| Literature DB >> 22874661 |
Anders Hovland1, Inger Hilde Nordhus, Trond Sjøbø, Bente A Gjestad, Birthe Birknes, Egil W Martinsen, Torbjørn Torsheim, Ståle Pallesen.
Abstract
BACKGROUND: Previous studies have suggested that physical exercise can reduce symptoms for subjects suffering from panic disorder (PD). The efficacy of this intervention has so far not been compared to an established psychotherapy, such as cognitive behaviour therapy (CBT). Assessment of controlled long-term effects and the clinical significance of the treatment are also lacking. AIM: To compare physical exercise to CBT as treatment for PD, and assess controlled long-term and clinically significant effects.Entities:
Mesh:
Year: 2012 PMID: 22874661 PMCID: PMC3675676 DOI: 10.1017/S1352465812000446
Source DB: PubMed Journal: Behav Cogn Psychother ISSN: 1352-4658
Figure 1.Consort diagram displaying the process of inclusion, allocation and attrition. PE = physical exercise a Includes subjects whose job, studies or distance of travel prevented participation.
Baseline characteristics of patients assigned to Physical Exercise (PE) or CBT
| All patients ( | PE ( | CBT ( | ||||
|---|---|---|---|---|---|---|
| Characteristic | % | % | % | |||
| Female | 29 | 80.6 | 15 | 88.2 | 14 | 73.7 |
| Marital status (e.g. living alone) | 10 | 27.8 | 7 | 41.2 | 3 | 15.8 |
| Employment 6 months prior to treatment | ||||||
| Full-time employed | 17 | 47.2 | 10 | 58.8 | 7 | 36.8 |
| Part-time employed | 10 | 27.8 | 4 | 23.5 | 6 | 31.6 |
| In rehabilitation or on sick leave | 4 | 11.1 | 1 | 5.9 | 3 | 15.8 |
| Without regular work | 3 | 8.3 | 2 | 11.8 | 1 | 5.3 |
| Student | 2 | 5.6 | 0 | 0 | 2 | 10.5 |
| Mean | Mean | Mean | ||||
| Age (years) | 37.9 | 8.6 | 38.1 | 8.6 | 37.8 | 8.9 |
| Years of education | 13.6 | 2.5 | 13.9 | 2.5 | 13.4 | 2.5 |
| Duration of PD | 10.1 | 9.5 | 12.3 | 10.7 | 8.2 | 8.1 |
| Test of physical fitness level (6MWT) | 570.5 | 90.1 | 593.1 | 70.5 | 550.3 | 103.7 |
| Body Mass Index | 26.7 | 5.8 | 26.9 | 6.2 | 26.6 | 5.5 |
| % | % | % | ||||
| Physical exercisea | 10 | 27.8 | 5 | 29.4 | 5 | 26.3 |
| Medication | ||||||
| SSRIs | 13 | 36.1 | 7 | 41.2 | 6 | 31.6 |
| Benzodiazepinesb | 5 | 13.9 | 3 | 17.6 | 2 | 10.5 |
| Previous treatment for PD | 14 | 38.9 | 6 | 35.3 | 8 | 42.1 |
| Agoraphobia | 29 | 80.6 | 13 | 76.5 | 16 | 84.2 |
| Axis 1 comorbidity | ||||||
| Depression | 14 | 38.9 | 6 | 35.3 | 8 | 42.1 |
| Social phobia | 15 | 41.7 | 8 | 47.1 | 7 | 36.8 |
| Single phobia | 17 | 47.2 | 7 | 41.2 | 10 | 52.6 |
| Generalised Anxiety Disorder | 16 | 44.4 | 8 | 47.1 | 8 | 42.1 |
| Health anxiety | 8 | 22.2 | 5 | 29.4 | 3 | 15.8 |
| Obsessive-Compulsive Disorder | 3 | 8.3 | 1 | 5.9 | 2 | 10.5 |
| Mean | Mean | Mean | ||||
| Number of comorbid axis 1 disorders | 2.1 | 1.2 | 2.2 | 1.4 | 2.1 | 0.9 |
| Number of comorbid axis 2 disorders | 0.4 | 0.6 | 0.4 | 0.6 | 0.4 | 0.6 |
Notes: No significant (p < .05) group differences were found. Both 6MWT and Body Mass Index (BMI) were assessed at pre-treatment. aRefers to ongoing (within last 14 days) level of physical exercise recommended for cardiorespiratory fitness or muscular strength as recommended by ACSM (Pollock et al., 1998).bRefers to the intermittent use of benzodiazepines (Valium, Stesolid, Imovane) within the last month.
Analyses of outcome measures
| Treatments | Comparisons | ||||||
|---|---|---|---|---|---|---|---|
| Physical Exercise ( | CBT ( | Between-groups effects | |||||
| Outcome measures | Mean ( | ES | Mean ( | ES | ES | Time × Group | |
| 1.71 (16, 544)* | |||||||
| 3.75 (2.28, 77.61)* | |||||||
| Baseline | 2.42 (0.57) | 2.37 (0.78) | 0.07 | [−0.58, 0.73] | |||
| Pre-treatment | 2.38 (0.65) | −0.06 | 2.40 (0.70) | 0.04 | −0.02 | [−0.68, 0.63] | |
| Post-treatment | 1.98 (0.74)a | −0.65 | 1.55 (0.55)a | −1.18 | 0.65 | [−0.02, 1.32] | |
| 6-month follow-up | 1.93 (0.75)a | −0.71 | 1.59 (0.76)a | −0.98 | 0.44 | [−0.22, 1.10] | |
| 12-month follow-up | 2.04 (0.68)a | −0.59 | 1.61 (0.75)a | −0.98 | 0.59 | [−0.08, 1.26] | |
| 3.93 (2.19, 74.28)* | |||||||
| Baseline | 1.79 (0.43) | 1.98 (0.70) | −0.32 | [−0.97, 0.34] | |||
| Pre-treatment | 1.79 (0.55) | 0.01 | 1.92 (0.58) | −0.09 | −0.21 | [−0.87, 0.45] | |
| Post-treatment | 1.61 (0.61) | −0.33 | 1.39 (0.53)a | −0.92 | 0.36 | [−0.29, 1.02] | |
| 6-month follow-up | 1.51 (0.55) | −0.54 | 1.44 (0.62)a | −0.79 | 0.12 | [−0.53, 0.78] | |
| 12-month follow-up | 1.64 (0.54) | −0.30 | 1.41 (0.58)a | −0.87 | 0.41 | [−0.25, 1.07] | |
| 1.15 (2.11, 71.62) | |||||||
| Baseline | 2.30 (0.52) | 2.23 (0.61) | 0.13 | [−0.52, 0.79] | |||
| Pre-treatment | 2.23 (0.45) | −0.16 | 2.12 (0.49) | −0.20 | 0.23 | [−0.43, 0.89] | |
| Post-treatment | 1.85 (0.58)a | −0.80 | 1.50 (0.38)a | −1.40 | 0.70 | [0.03, 1.38] | |
| 6-month follow-up | 1.75 (0.52)a | −1.04 | 1.44 (0.33)a | −1.58 | 0.72 | [0.05, 1.40] | |
| 12-month follow-up | 1.76 (0.55)a | −0.99 | 1.50 (0.35)a | −1.45 | 0.57 | [−0.10, 1.24] | |
| 4.08 (2.81, 95.43)* | |||||||
| Baseline | 2.86 (0.60) | 2.72 (0.75) | 0.20 | [−0.45, 0.86] | |||
| Pre-treatment | 2.55 (0.55) | −0.54 | 2.48 (0.71) | −0.32 | 0.10 | [−0.56, 0.75] | |
| Post-treatment | 2.25 (0.80)a | −0.85 | 1.55 (0.43)a | −1.87 | 1.07 | [0.37, 1.77] | |
| 6-month follow-up | 2.13 (0.68)a | −1.11 | 1.57 (0.54)a | −1.73 | 0.90 | [0.21, 1.59] | |
| 12-month follow-up | 2.12 (0.69)a | −1.12 | 1.70 (0.63)a | −1.45 | 0.64 | [−0.03, 1.31] | |
| 1.00 (8, 272) | |||||||
| Baseline | 5.94 (2.05) | 6.42 (1.64) | −0.25 | [−0.91, 0.40] | |||
| Pre-treatment | 5.76 (1.75) | −0.09 | 6.11 (1.49) | −0.19 | −0.21 | [−0.87, 0.44] | |
| Post-treatment | 2.82 (2.74)a | −1.26 | 1.79 (1.87)a | −2.57 | 0.43 | [−0.23, 1.10] | |
| 6-month follow-up | 2.00 (2.24)a | −1.80 | 1.74 (2.05)a | −2.47 | 0.12 | [−0.54, 0.77] | |
| 12-month follow-up | 3.06 (2.88)a | −1.13 | 2.00 (2.13)a | −2.27 | 0.41 | [−0.25, 1.07] | |
| Baseline | 1.47 (1.13) | 1.79 (1.32) | −0.25 | [−0.91, 0.40] | |||
| Pre-treatment | 1.35 (1.12) | −0.10 | 1.68 (1.34) | −0.08 | −0.26 | [−0.92, 0.40] | |
| Post-treatment | 0.76 (1.25) | −0.58 | 0.68 (0.95) | −0.95 | 0.07 | [−0.58, 0.73] | |
| 6-month follow-up | 0.53 (1.13) | −0.82 | 0.58 (0.90)a | −1.05 | −0.05 | [−0.70, 0.61] | |
| 12-month follow-up | 0.82 (1.13) | −0.56 | 0.47 (0.77)a | −1.20 | 0.36 | [−0.30, 1.02] | |
| 0.75 (6, 204) | |||||||
| Baseline | 6.53 (1.42) | 6.79 (1.32) | −0.19 | [−0.84, 0.47] | |||
| Pre-treatment | 6.24 (1.72) | −0.18 | 6.21 (1.81) | −0.36 | 0.02 | [−0.64, 0.67] | |
| Post-treatment | 2.82 (2.79)a | −1.64 | 2.37 (2.50)a | −2.17 | 0.17 | [−0.49, 0.82] | |
| 6-month follow-up | 2.59 (2.81)a | −1.73 | 2.11 (2.31)a | −2.44 | 0.18 | [−0.47, 0.84] | |
| Baseline | 1.35 (1.12) | 1.79 (1.36) | −0.34 | [−1.00, 0.31] | |||
| Pre-treatment | 2.00 (1.32) | 0.52 | 1.58 (1.39) | −0.15 | 0.30 | [−0.36, 0.96] | |
| Post-treatment | 0.76 (1.25) | −0.49 | 0.63 (0.90)a | −0.99 | 0.12 | [−0.54, 0.77] | |
| 6-month follow-up | 0.65 (1.22) | −0.58 | 0.58 (0.96)a | −1.01 | 0.06 | [−0.59, 0.72] | |
| 1.16 (20, 540) | |||||||
| Baseline | 27.76 (10.89) | 26.37 (9.71) | 0.13 | [−0.52, 0.79] | |||
| Pre-treatment | 22.06 (10.78) | −0.51 | 22.32 (10.46) | −0.39 | −0.02 | [−0.68, 0.63] | |
| Post-treatment | 15.65 (14.18)a | −0.94 | 10.11 (7.71)a | −1.82 | 0.48 | [−0.18, 1.15] | |
| 6-month follow-up | 13.59 (11.89)a | −1.21 | 9.42 (8.51)a | −1.82 | 0.40 | [−0.26, 1.06] | |
| 12-month follow-up | 13.95 (11.81)a | −1.19 | 10.59 (9.82)a | −1.58 | 0.30 | [−0.35, 0.96] | |
| Baseline | 50.06 (10.76) | 54.47 (9.00) | −0.44 | [−1.10, 0.22] | |||
| Pre-treatment | 50.18 (13.11) | 0.01 | 51.32 (8.61) | −0.35 | −0.10 | [−0.76, 0.55] | |
| Post-treatment | 43.71 (13.93) | −0.50 | 42.16 (10.19)a | −1.25 | 0.13 | [−0.53, 0.78] | |
| 6-month follow-up | 42.65 (13.40)a | −0.60 | 41.93 (10.92)a | −1.23 | 0.06 | [−0.60, 0.71] | |
| 12-month follow-up | 43.18 (14.14) | −0.53 | 41.21 (10.65)a | −1.32 | 0.15 | [−0.50, 0.81] | |
| Baseline | 44.41 (9.62) | 43.11 (8.66) | 0.14 | [−0.52, 0.80] | |||
| Pre-treatment | 41.35 (11.29) | −0.28 | 42.16 (8.76) | −0.11 | −0.08 | [−0.73, 0.58] | |
| Post-treatment | 36.65 (11.96) | −0.70 | 35.42 (10.15)a | −0.80 | 0.11 | [−0.55, 0.76] | |
| 6-month follow-up | 35.82 (9.75)a | −0.87 | 33.53 (9.74)a | −1.02 | 0.23 | [−0.43, 0.89] | |
| 12-month follow-up | 36.59 (14.31) | −0.63 | 38.37 (10.95) | −0.47 | −0.14 | [−0.79, 0.52] | |
| Baseline | 18.24 (10.28) | 21.89 (7.78) | −0.40 | [−1.06, 0.27] | |||
| Pre-treatment | 14.59 (9.27) | −0.36 | 19.00 (8.99) | −0.34 | −0.47 | [−1.14, 0.19] | |
| Post-treatment | 9.71 (9.25)a | −0.85 | 10.58 (9.29)a | −1.29 | −0.09 | [−0.75, 0.56] | |
| 6-month follow-up | 9.71 (8.77)a | −0.87 | 11.32 (8.06)a | −1.31 | −0.19 | [−0.84, 0.47] | |
| 12-month follow-up | 10.18 (11.13)a | −0.73 | 11.16 (8.99)a | −1.25 | −0.10 | [−0.75, 0.56] | |
| Baseline | 1.34 (1.52) | 1.08 (1.26) | −0.19 | [−0.47, 0.84] | |||
| Pre-treatment | 1.19 (1.18) | 0.11 | 0.90 (1.52) | 0.13 | −0.21 | [−0.44, 0.87] | |
| Post-treatment | 1.64 (1.33) | −0.20 | 1.56 (1.65) | −0.33 | −0.05 | [−0.61, 0.70] | |
| 6-month follow-up | 1.87 (1.52) | −0.34 | 1.55 (1.62) | −0.32 | −0.20 | [−0.46, 0.85] | |
| 12-month follow-up | 1.85 (1.66) | −0.31 | 1.54 (1.84) | −0.29 | −0.17 | [−0.48, 0.83] | |
Notes: MANOVAs assess combined effects of the different groups of outcome measures. Significant results are further assessed with subsequent ANOVAs for the implicated outcome measures. Effect sizes for each treatment are reported with reference to baseline values. All effect sizes are calculated with pooled standard deviations. Between-groups effects are reported with positive values indicating effect in favour of CBT. For the ANOVAs, degrees of freedom were corrected using Greenhouse-Geisser estimates. * = p < .05. aSignificant within-group effect from Baseline to corresponding time-point (Bonferroni-corrected). bValens of effect sizes were changed to be in concordance with the rest of the Table.
Figure 2.Physical exercise (PE) and CBT compared over time on the primary outcome inventories. Bars represent standard error of the mean
Figure 3.Reliable and clinically significant change from baseline to 12 month follow-up. Criteria are applied to MI – Alone, and are accumulated stepwise. Freedom from panic is based on the score on the panic frequency-item in the self-report measure Panic Attack Scale. PE = physical exercise. * = p < .05 (two-sided Fisher's exact test)